Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database

Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database

ObjectivesOver the years when disease-modifying antirheumatic drugs (DMARDs) have been used in rheumatoid arthritis patients, reports of malignancies have emerged. This study aims to investigate the association between malignancies and DMARDs by using data extracted from the Food and Drug Administra...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wan Xiong, Yilin Li, Lin Hu, Gefei He, Juanjuan Huang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Pharmacology
Subjects:	DMARDs malignancy rheumatoid arthritis FAERS pharmacovigilance
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1458500/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis
by: Heng Chen, et al.
Published: (2024-12-01)

Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
by: Chuang Yang, et al.
Published: (2025-02-01)

Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
by: Ximu Sun, et al.
Published: (2025-02-01)

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database
by: Bu-kun Zhu, et al.
Published: (2025-02-01)

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases
by: Qian Liu, et al.
Published: (2024-11-01)

Improvement in rheumatoid sarcopenia with biological therapy; muscle ultrasound study
by: Zehra Özsoy, et al.
Published: (2024-11-01)

Pharmacological pain management in patients with rheumatoid arthritis: a narrative literature review
by: Natasha Cox, et al.
Published: (2025-01-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)

Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database
by: Hong Pan, et al.
Published: (2024-12-01)

Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)

Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
by: Yifan Hong, et al.
Published: (2024-12-01)

Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
by: Hui Chen
Published: (2025-01-01)

Safety and efficacy of an Anti-CD20 Monoclonal antibody (RedituxTM) In Indian patients with seropositive rheumatoid arthritis
by: Arun Hegde, et al.
Published: (2018-01-01)

Drug-induced heart failure: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Youqi Huang, et al.
Published: (2025-01-01)

A real-world pharmacovigilance study of neuroleptic malignant syndrome based on FDA adverse event reporting system
by: Yu Zhang, et al.
Published: (2024-12-01)

Influence of Medication on Flare Up and Infection After Elective Orthopedic Surgery in Rheumatoid Arthritis Patient – A Narrative Review
by: Yaldi Rosadi, et al.
Published: (2020-10-01)

Unveiling the Hidden Risks: An Update Decade-Long Analysis of Abraxane-Related Adverse Events from the FAERS Database
by: Zhao YC, et al.
Published: (2024-11-01)

Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database
by: Peiyang Cao, et al.
Published: (2025-01-01)

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

Real world pharmacovigilance assessment of drug related macular degeneration risks
by: Xiaodong Chen, et al.
Published: (2025-01-01)

Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database
by: Jiancheng Qian, et al.
Published: (2024-12-01)

Preferable effect of CTLA4-Ig on both bone erosion and bone microarchitecture in rheumatoid arthritis revealed by HR-pQCT
by: Naoki Iwamoto, et al.
Published: (2024-11-01)

Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases
by: Xianyu Dai, et al.
Published: (2025-01-01)

Different prevalence and spectrum of malignancy between Chinese patients and American patients with rheumatoid arthritis: a comparative study
by: Zhi-Ming Ouyang, et al.
Published: (2024-12-01)

Predictors of radiological progression of rheumatoid arthritis while receiving conventional synthetic disease-modifying antirheumatic drugs
by: O. B. Iaremenko, et al.
Published: (2024-12-01)

A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database
by: Ya-Jun Zhang, et al.
Published: (2024-12-01)

Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents
by: Andrea Picchianti-Diamanti, et al.
Published: (2025-02-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)

Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry
by: Masayoshi Harigai, et al.
Published: (2024-07-01)

Predictors of response to bDMARDs and tsDMARDs in psoriatic arthritis: a pilot study on the role of musculoskeletal ultrasound
by: Giacomo Cozzi, et al.
Published: (2024-12-01)

Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults
by: Hao Li, et al.
Published: (2025-01-01)

Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS
by: Ke Wang, et al.
Published: (2025-01-01)

Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system
by: Yanjun Lu, et al.
Published: (2024-12-01)

Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis
by: Hui Guo, et al.
Published: (2024-11-01)

High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database
by: Zhishen Ruan, et al.
Published: (2025-01-01)

Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS)
by: Hui Gao, et al.
Published: (2025-01-01)

Drug-induced hearing disorders: a disproportionality analysis of the FAERS database
by: Baojian Li, et al.
Published: (2024-11-01)

Candidate antirheumatic genotherapeutic plasmid constructions have low immunogenicity
by: T. S. Nepomnyashchikh, et al.
Published: (2017-05-01)